Regeneron Pharmaceuticals (REGN) Other Non-Current Liabilities (2009 - 2026)

Regeneron Pharmaceuticals' Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $2.1 billion for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 26.98% year-over-year to $2.1 billion in Q1 2026; TTM through Mar 2026 was $2.1 billion, a 26.98% increase from a year earlier, with the FY2025 full-year figure at $2.0 billion, up 28.47% from the prior year.
• Other Non-Current Liabilities improved to $2.1 billion in Q1 2026 per REGN's latest filing, from $2.0 billion in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $2.1 billion in Q1 2026 and bottomed at $43.7 million in Q3 2023.
• The 5-year median for Other Non-Current Liabilities is $908.5 million (2024), against an average of $1.2 billion.
• Across the five-year window, Other Non-Current Liabilities slumped 92.7% in 2023 and soared 3432.27% in 2024, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $638.0 million in 2022, then jumped by 33.87% to $854.1 million in 2023, then jumped by 83.98% to $1.6 billion in 2024, then gained by 28.47% to $2.0 billion in 2025, then increased by 5.32% to $2.1 billion in 2026.
• Per Business Quant, the three latest REGN Other Non-Current Liabilities figures stand at $2.1 billion (Q1 2026), $2.0 billion (Q4 2025), and $1.9 billion (Q3 2025).